logo_lysogene

About the Company

Lysogene (Euronext Paris: LYS.PA) is a French biotechnology Company focused on developing novel gene therapies for lysosomal storage disorders. The Company’s lead candidate, LYS-SAF302, is an adeno-associated virus (AAV) capable of delivering a missing gene into patients with Mucopolysaccharidosis Type IIIA (MPS IIIA), an orphan indication for which there are no treatments. The Company recently went public through an IPO on the Euronext Paris exchange and plans to initiate a pivotal Phase II/III trial in MPS IIIA patients by the first quarter of 2018. Lysogene is also pursing GM1 gangliosidosis, another orphan indication, and may opt to leverage their platform and expertise to move into additional rare CNS diseases.

Source: LifeSci Capital, LLC research report

Research analyst certification and important disclosures can be found in the full research report. To access the full research report, please click on the link below.


Recent Research